Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Absci Corp (ABSI)

Absci Corp (ABSI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 288,745
  • Shares Outstanding, K 92,844
  • Annual Sales, $ 4,780 K
  • Annual Income, $ -100,960 K
  • 60-Month Beta 0.86
  • Price/Sales 63.10
  • Price/Cash Flow N/A
  • Price/Book 0.95
Trade ABSI with:

Options Overview Details

View History
  • Implied Volatility 95.25% ( -17.61%)
  • Historical Volatility 94.90%
  • IV Percentile 30%
  • IV Rank 15.52%
  • IV High 347.55% on 08/26/22
  • IV Low 48.88% on 06/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 475
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 9,329
  • Open Int (30-Day) 8,824

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.31
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.05 +2.13%
on 09/23/22
4.68 -33.55%
on 08/25/22
-1.14 (-26.82%)
since 08/23/22
3-Month
3.02 +2.98%
on 07/13/22
7.04 -55.82%
on 08/11/22
-0.64 (-17.07%)
since 06/23/22
52-Week
2.93 +6.14%
on 06/13/22
18.12 -82.84%
on 11/08/21
-8.35 (-72.86%)
since 09/23/21

Most Recent Stories

More News
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of 0% and 38.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ABSI : 3.11 (-4.31%)
ALBO : 18.73 (-2.80%)
Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 1.61% and 20.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 0.9152 (unch)
ABSI : 3.11 (-4.31%)
Absci Reports Second Quarter 2022 Financial Results and Business Update

Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 ...

ABSI : 3.11 (-4.31%)
The Zacks Analyst Blog Highlights Absci Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics

Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

AXLA : 1.6200 (-7.43%)
PLRX : 19.83 (-3.41%)
FRLN : 0.7695 (+11.94%)
ABSI : 3.11 (-4.31%)
DICE : 18.56 (+1.14%)
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CRSP : 63.16 (-2.68%)
ABSI : 3.11 (-4.31%)
Absci to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

VANCOUVER, Wash. and NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep...

ABSI : 3.11 (-4.31%)
Absci to Participate in the SVB Securities CybeRx: Big Data, A.I. & Machine Learning in Healthcare Event

VANCOUVER, Wash. and NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep...

ABSI : 3.11 (-4.31%)
Absci Prepares for Next Stage of Growth with Executive Human Resources and Marketing Hires

VANCOUVER, Wash. and NEW YORK, July 14, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep...

ABSI : 3.11 (-4.31%)
Absci Enters Multi-Program Collaboration with Emerging Biotech Partner

Seven program deal with stealth-mode ADC company to leverage Absci’s Bionic Protein™ technology...

ABSI : 3.11 (-4.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company's Creation(TM) Platform involved in discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single...

See More

Key Turning Points

3rd Resistance Point 3.43
2nd Resistance Point 3.34
1st Resistance Point 3.22
Last Price 3.11
1st Support Level 3.02
2nd Support Level 2.93
3rd Support Level 2.82

See More

52-Week High 18.12
Fibonacci 61.8% 12.32
Fibonacci 50% 10.53
Fibonacci 38.2% 8.73
Last Price 3.11
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar